Post
newsbot
CONCORDBIO
Concord Biotech gets final approval from USFDA for marketing Teriflunomide Tablets
News Summary
• Concord Biotech has received final approval from the USFDA for its Teriflunomide Tablets, which are used to treat relapsing forms of multiple sclerosis.
• The approval highlights Concord Biotech's ability to develop and market differentiated products in the U.S. pharmaceutical market.
• The market size for Teriflunomide tablets is approximately $402 million in the U.S. and $908 million globally, presenting significant growth opportunities for the company.
Apr 9 11:19 PM